Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.

Christoph A Schatz Sabine Zitzmann-Kolbe Ingrid Moen Monika Klotz Shankari Nair Stefan Stargard Roger M Bjerke Katrine Wickstrøm Biseth Yuan Zeng Feng Bård Indrevoll Véronique Cruciani Jenny Karlsson Bernard Haendler Carsten H Nielsen Maria Z Alfsen Stefanie Hammer Hartwig Hennekes Alan S Cuthbertson Urs B Hagemann Aasmund Larsen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

These results provide a strong rationale to investigate 225Ac-pelgi in patients with prostate cancer. A clinical phase 1 study has been initiated (NCT06052306).

Keyphrases

prostate cancer
cancer therapy
radical prostatectomy
pet ct
drug delivery
clinical trial
pet imaging
stem cells
double blind
computed tomography